SCHEMBL2420669

SCHEMBL2420669

COc1cccc(C2c3cccn3CCN2C(=O)CCC(=O)NCc2ccncc2)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.51
MAPT P10636 5/20 0.51
KMT2A Q03164 4/20 0.51
ADRA2C P18825 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
MEN1 O00255 1/20 0.45
RECQL P46063 1/20 0.45
GAA P10253 2/20 0.44
MAPK1 P28482 1/20 0.44
LMNA P02545 1/20 0.43
RAB9A P51151 1/20 0.43
TP53 P04637 1/20 0.40
KIF11 P52732 1/20 0.39
NAMPT P43490 1/20 0.39
HTR1A P08908 1/20 0.39
HTR7 P34969 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2418919 0.80 ALDH1A1 (0.54) ALDH1A1MAPTKMT2AADRA2CSMN1; SMN2
SCHEMBL2419969 0.80 ALDH1A1 (0.51) ALDH1A1MAPTKMT2AADRA2CSMN1; SMN2
SCHEMBL3857927 0.78 ALDH1A1 (0.37) ALDH1A1MAPTKMT2AADRA2CSMN1; SMN2
SCHEMBL13263593 0.77 ALDH1A1 (0.49) ALDH1A1MAPTKMT2AADRA2CSMN1; SMN2
SCHEMBL2421599 0.74 ADRA2C (0.51) ALDH1A1MAPTKMT2AADRA2CSMN1; SMN2
SCHEMBL2424265 0.74 ADRA2C (0.45) ALDH1A1MAPTKMT2AADRA2CSMN1; SMN2
SCHEMBL2416409 0.73 ALDH1A1 (0.47) ALDH1A1MAPTKMT2AADRA2CSMN1; SMN2
SCHEMBL2424341 0.73 ALDH1A1 (0.51) ALDH1A1MAPTADRA2CSMN1; SMN2GAA
SCHEMBL2422600 0.72 MAPT (0.48) ALDH1A1MAPTKMT2AADRA2CSMN1; SMN2
SCHEMBL1267469 0.71 ALDH1A1 (0.72) ALDH1A1MAPTKMT2AADRA2CSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017772-B2 Substituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain GRUENENTHAL GMBH (DE) 2011-09-13 US claimed
US-20100004252-A1 SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN GRUENENTHAL GMBH (DE) 2010-01-07 US claimed
US-7625900-B2 Sutstituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain GRUENENTHAL GMBH (DE) 2009-12-01 US claimed
US-20080167315-A1 Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain GRUENENTHAL GMBH (DE) 2008-07-10 US claimed
US-8017772-B2 Substituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain GRUENENTHAL GMBH (DE) 2011-09-13 US disclosed
US-20100004252-A1 SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN GRUENENTHAL GMBH (DE) 2010-01-07 US disclosed
US-7625900-B2 Sutstituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain GRUENENTHAL GMBH (DE) 2009-12-01 US disclosed
US-20080167315-A1 Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain GRUENENTHAL GMBH (DE) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004252-A1 SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN KCNQ2, KCNQ1, KCNJ2 ALDH1A1 2817/4885MAPT 1735/4885KMT2A 770/4885
US-20080167315-A1 Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain KCNQ2, KCNQ1, KCNJ2 ALDH1A1 2817/4885MAPT 1735/4885KMT2A 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.